Axon's financial profile shows significant balance sheet expansion alongside substantially reduced profitability and operating cash flow generation.
The company appears to be in a major investment phase, with R&D spending meaningfully higher and capital expenditures substantially increased, but this is coming at the cost of current profitability and cash generation. The near-doubling of total liabilities alongside expanded current assets suggests either significant debt financing or operational scaling that investors should monitor closely.
Axon's balance sheet expanded dramatically with total assets growing 56% and total liabilities increasing 75%, indicating significant capital deployment or financing activity. However, operational performance deteriorated meaningfully with net income substantially reduced and operating cash flow declining by nearly half. The combination of substantially higher R&D spending and increased capital expenditures suggests heavy investment in growth initiatives, but the sharp decline in cash generation raises questions about the near-term return on this capital deployment.
Liabilities grew 75% — significant increase in debt or obligations, assess impact on financial flexibility.
Capital expenditure jumped 72.9% — major investment cycle underway; assess returns on deployment.
Net income declined 66.9% — review whether driven by operations, interest costs, or non-recurring items.
Current assets grew 61.6% — improving short-term liquidity or inventory/receivables build.
Asset base grew 56.4% — expansion through organic growth, acquisitions, or capital deployment.
R&D investment increased 55% — signals commitment to future product development, though near-term margin impact.
Receivables surged 53.7% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.
Operating cash flow fell 48.2% — earnings quality concerns; investigate working capital changes and non-cash items.
Current liabilities surged 47.4% — significant near-term obligations; verify ability to meet short-term debt.
SG&A up 39.8% — significant increase in sales or administrative costs, monitor impact on operating leverage.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →